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Abstract
The combined deletion of 1p and 19q chromosomal arms is frequent in oligodendrogliomas (OD) and has recently been
shown to be mediated by an unbalanced t(1;19) translocation. Recent studies of 1p/19q co-deleted OD suggest that the
NOTCH2 gene is implicated in oligodendrocytedifferentiation and may be involved in this rearrangement. Theobjective of the
presentstudy wastoanalyzethe NOTCH2locuseitherasa chromosomaltranslocation locusthatmaybealtered bythe 1p/19q
recurrent rearrangement or as a gene that may be inactivated by a two hit process. We performed an array-CGH analysis of 15
ODs presenting 1p/19q co-deletion using a high-density oligonucleotide microarray spanning 1p and 19q pericentromeric
regionswith377 bpaverageprobespacing.Weshowedthatthe 1pdeletionextendstothecentromereofchromosome 1and
includes the entire NOTCH2 gene. No internal rearrangement of this gene was observed. This strongly suggests that the t(1;19)
translocation does not lead to an abnormal NOTCH2 structure. The analysis of the entire NOTCH2 coding sequence was
performed in four cases and did not reveal any mutation therefore indicating that NOTCH2 does not harbor genetic
characteristics of a tumor suppressor gene. Finally, the detailed analysis of chromosome 19 pericentromeric region led to the
identification of two breakpoint clusters at 19p12 and 19q11–12. Interestingly, these two regions share a large stretch of
homology. Together with previous observations of similarities between chromosome 1 and 19 alphoid sequences, this
suggests that the t(1;19) translocation arises from complex intra and interchromosomal rearrangements. This is the first
comprehensive deletion mapping by high density oligo-array of the 1p/19q co-deletion in oligodendroglioma tumors using a
methodological approach superior to others previously applied. As such this paper provides clear evidence that the NOTCH2
gene is not physically rearranged by t(1;19) translocation of oligodendroglioma tumors.
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Introduction
Concurrent deletion of chromosomal arms 1p and 19q is the
most common genetic alteration in oligodendroglial tumors [1–6].
Indeed, it is detected in 50% to 80% of oligodendroglial tumors
including oligodendrogliomas (ODs) and oligoastrocytomas [7–9].
In contrast 1p/19q codeletion is uncommon in diffuse astrocytomas
[3]. Combined 1p/19q allelic loss is observed in both grade II and
grade III ODs. In patients affected with oligodendroglioma this
genotype is associated with increased progression-free and overall
survival as well as a better responsiveness to durable response to
chemotherapy [4,10,11,12]. We have previously constructed a
1 Mb resolution BAC array containing 3342 genomic clones
covering the human genome and applied it to profile DNA copy
number alterations of an extended series of 112 gliomas, including
49ODs[13].Inthecourseofthisstudy,weobservedthepresenceof
a consistent chromosome 1 breakpoint in the vicinity of the
centromere in tumors presenting 1p/19q allelic loss. Based on this
observation, we hypothesized that the break itself rather than the
deletion might play a role in tumor development, supporting
thereforethe presenceof a t(1;19) translocation.This hypothesis was
further reinforced by studies of Jenkins et al. [14] and Griffin et al.
[15] showing that an unbalanced t(1;19)(q10;p10) translocation
accounts for the 1p/19q pattern and that this combined co-deletion
results from the loss of one of the two translocation derivatives.
Moreover, we and others [13,16] found that 1p juxta-centromeric
deletion breakpoints map within the region encoding the NOTCH2
gene which is implicated in oligodendrocyte differentiation [17] and
brain tumor oncogenesis [18].
NOTCH2 constitutes a very attractive candidate to be
specifically rearranged by the t(1;19) translocation. Rearrange-
ment could lead to the formation of a fusion gene or to truncation
of the gene. To more thoroughly investigate the NOTCH2 region
we constructed a high density, locus-specific oligonucleotide array-
CGH covering the entire 1p pericentromeric region and applied it
to profile 11 ODs with 1p/19q co-deletion. The chromosome 19
pericentromeric region was also investigated using the same
approach. Finally, in order to further evaluate a potential tumor
PLoS ONE | www.plosone.org 1 January 2009 | Volume 4 | Issue 1 | e4107suppressor genetic model we searched for point mutations of the
NOTCH2 gene in four of our OD cases.
Results
NOTCH2 as a candidate target of the pericentromeric
t(1;19) translocation in oligodendrogliomas
Figure 1 displays chromosome 1 BAC-array results for two ODs
DNAs, representative of the series of 49 ODs previously described
[13]. In all cases, decreased tumor/normal fluorescence ratios,
indicative of a deletion in the tumor DNA, were detected starting
from BAC RP11-323K8 to the telomere of 1p (Figure 1).
Conversely, normal fluorescence ratios were observed from BAC
RP11-114O18 to the telomere of 1q. These results strongly
suggested that a recurrent chromosome breakpoint, lying between
BAC RP11-323K8 and BAC RP11-114O18 mapping at physical
position 120,191,966–120,379,651 and 120,191,966–120,379,651
on chromosome 1, was a characteristic feature of ODs with 1p/
19q co-deletion. Intriguingly, this region is included within
NOTCH2. Given that the 1p/19q co-deletion pattern has been
recently linked to a t(1;19) chromosome translocation, this
suggested that the chromosome 1 breakpoint may lie within the
NOTCH2 gene. However, this putative breakpoint coincides with a
transition from a single copy region (BAC RP11-323K8) to a
segmental duplication (BAC RP11-114O18). Indeed, the sequence
of this last BAC is duplicated at 1q21.1 (Figure 1B) which encodes
a truncated copy of NOTCH2, NOTCH homolog 2 N-terminal
like (N2N). Unlike common repeats (e.g. Alu or long interspersed
nuclear elements (LINEs), the duplicated sequences in BAC clones
resist complete blocking by human Cot-1 DNA, specifically when
duplications are large and highly identical [19]. Therefore we
could not conclude from these experiments whether the
chromosome 1 breakpoint was localized within the NOTCH2
gene or whether the apparent position of this break was falsely
attributed to the presence of a segmental duplication.
Exclusion of NOTCH2 as candidate target of t(1p;19q)
translocation–high density loci-specific oligonucleotide
array
To investigate in depth the putative breakpoint regions we
constructed a high density, oligonucleotide probes-based array
(Agilent Technologies) providing high resolution over the
Figure 1. Detection of chromosome 1p recurrent deletions in oligodendrogliomas using 1 Mb BAC array-CGH. The vertical line
denotes the centromere of chromosome (centr). The X-axis displays the physical position on chromosome 1 in megabases. A position landmark is
indicated every 50 BACs. The Y-axis denotes the average normalized fluorescence ratio (ratio of means for the intensities between test/tumor and
reference/normal DNA). (A) Array-CGH profiles illustrating 1p deletion in two selected oligodendrogliomas (OD16 and OD839) presenting 1p/19q co-
deletion pattern. The box centers on the centromere and pericentromeric region shown in figure 1B. (B) Detailed view of 181 Kb recurrent deletion
breakpoint segment. The blue diamonds highlight the supplementary clones in the improved version of a 1 Mb BAC array used in this analysis. Black
arrows above the genes show the orientation of their transcription. The position of the distal end of each BAC is indicated. The lower part of the
figure shows an enlargement of the box with indication of BAC clones (open bars), the NOTCH2 gene (black bar) and segmental duplications (Dupl,
orange bar).
doi:10.1371/journal.pone.0004107.g001
NOTCH2 and 1p/19q Co-Deletion
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loci-specific array was applied to profile OD DNAs derived from
15 patients. Each tumor DNA was paired with corresponding
peripheral blood-derived DNA of the patient and with normal
male DNA in individual experiments (used as references).
The 1.8 Mb synthesized 1p pericentromeric-specific region
consisted of 4262 measurement points of varying repeat/
duplication content including 478 probes covering the NOTCH2
gene. As shown in Figure 2A the general distribution of
aberrations defined by this high-resolution array supported the
existence of 1p deletion in all studied cases. This figure displays
output from the analysis of a representative case, illustrating a
contiguous 165 kb region, telomeric to NOTCH2 gene, (chromo-
some 1p position 119,457,515–119,622,059) covered by 500
probes. The probes fall into two major groups (Figure 2A, 2B).
The first group mainly includes single copy probes, as assessed by a
single hit through whole-genome BLAT analysis and indicated by
red diamonds on the figure, which display average log2
fluorescence ratios close to 21 corresponding to a deletion profile.
The second group exhibits normal (close to 0) log2 fluorescence
ratios and mostly contains probes with multiple BLAT hits. As
shown in figure 2B, the NOTCH2 region can be divided in two
segments. The 39 part contains numerous single copy probes and
presents a clear deleted profile whereas the 59 duplicated end
shows normal log2 ratios. These oligonucleotide array results are
in perfect agreements with the BAC array data described above
showing convergence of the apparent distal breakpoint of the
deletion with the starting point of NOTCH2 intrachromosomal
duplication. In order to define reliable copy number changes we
selected the probes for which the BLAT search displayed only a
single chromosomal position within human genome with 100%
sequence identity (probes indicated by red diamonds in Figure 2A).
As a result, a group of 851 unique probes on chromosome 1,
including 128 data points covering the NOTCH2 gene, was
extracted and is visualized on the graph (Figure 2C). Strikingly, 16
unique data points located centromeric of the NOTCH2 gene
enclosed by the chromosomal position 120,874,063–121,032,434
clearly indicated consistently decreased fluorescence ratios
(Figure 2C, 2D) in all studied cases. To confirm that the deletion
extended to the centromere, we further performed LOH-
associated SNP loci analysis on five selected 1p/19q oligodendro-
glioma cases using a panel of 39 single copy SNP (single-nucleotide
polymorphisms) markers encompassing the NOTCH2 locus. This
analysis showed that informative SNPs, being proximal, within or
distal to NOTCH2 exhibited loss-of-heterozygosity profiles.
Figures 2E and 2F show representative results for SNPs intragenic
(Ea and Eb) or proximal to NOTCH2 part (Fc to Fg). All above
outlined results, therefore, confirmed the presence of continuous
1p deletions extending all the way to the centromere and
consequently ruled out the chromosome 1 translocation break-
point being localized within the NOTCH2 gene.
Mutation analysis of the NOTCH2 gene sequence
An hypothesis which may account for the localization of the
t(1;19) translocation breakpoint proximal to NOTCH2 may rely on
a two-hit inactivation process with one allele of NOTCH2 being
inactivated by the deletion and the remaining one by point
mutation. To test this hypothesis, we screened for somatic
mutations the complete coding sequence of NOTCH2 gene in
four tumor and paired peripheral blood derived DNAs. The 34
exon sequences of this gene transcript span 9371 bp and encode a
protein of 2555 amino acids. Sequence analyses of these genomic
DNAs revealed no heterozygous mutation in either of the
NOTCH2 exons (data not shown).
Two clusters of translocation breakpoints on
chromosome 19
As outlined above, the hemizygous deletion of the 19q arm
(Figure 3A) strongly associates with 1p single copy loss, both events
being mediated by a t(1;19) translocation with juxta-centromeric
breakpoints. Therefore, we applied a chromosome 19 pericentro-
meric high density genomic microarray to precisely detect putative
breakpoint sites. This array resolves the pericentromeric region of
1.4 Mb (positions on chromosome 19 23,940,099–24,422,759 and
32,426,023–33,387,097;build 36.1) into3417 distinct measurement
points with an average probe spacing of 379 bp. This 19q specific
array proved to be a sensitive assay for detecting deletion of the 19q.
In the course of these analyses three types of profile were retrieved.
The first type consisted of a complete deletion of the 19q analyzed
region extendingdown to chromosome 19ppericentromericregion.
It was observed in 5/15 cases (Figure 3B). The second type,
observed in 6/15 cases, was characterized by a transition from
normal to deleted ratios within the analyzed 19q region (Figure 3C).
The third class of profile, detected in 4 cases, revealed the
coexistence of 19q loss with different patterns of gains/amplifica-
tions (Figure 3D). The positions of the breakpoints were slightly
different from one case to the other (Figure 3E, 3F, for breakpoint
positions information,seesupplementary Table S1)and defined one
major breakpoint cluster in 19p and another one on 19q. The 19p
and 19q regions were determined to be 5 kb and 157 kb in size,
respectively.Thetwoclusterregions areshown onfigure 3Eand 3F.
Using publicly available databases we reviewed the genes present in
these regions and observed that only in the 19q region are there
annotated gene sequences; namely the non-RefSeq transcripts
AK075337, AK094188, AK055559, BC024732 and DQ586608.
Both regions are also known to be encompassed by putative copy
number polymorphism variation (CNP) (Figure 3E, 3F); however
we did not find variation of these fragments in any of 15-germline
DNA samples.
Discussion
Our study follows up previous works that identified the existence
ofa nearly consistentdeletionhotspot withinpericentromericregion
of 1p in ODs with 1p/19q allelic loss [13]. Interestingly, recent
observationsby Griffin et al. [15] and Jenkinset al. [14] also support
the presence of a 1;19 translocation accompanied by a loss of one of
the two translocation derivatives. The fact that NOTCH2 is located
near the chromosome 1 centromere made analysis of this interval a
considerable challenge. Pericentromeres are among the most
complex regions within human genome and contain several inter-
and intra-chromosomal duplications and repeat sequences which
increase in number when approaching the centromere [20–22].
The high density oligonucleotide array-CGH we applied is superior
to previous methodological approaches used in the analysis of 1p/
19qco-deletedOD[2,10,23,24]withthemajoradvantagebeingthe
high resolution of analysis due to the large number of independent
measurement points completely covering NOTCH2 gene and
extending to the most centromeric point on the human reference
sequence. We found that deletion on chromosomal arm 1p is in fact
continuous and that its endpoint apparently lies within the
centromere. Moreover, an additional detailed mutation analysis of
allcodingNOTCH2exonsinfour1p/19qcodeletedODspresenting
LOH showed no evidence of somatic NOTCH2 mutations. This
indicates that the deletion of one allele of NOTCH2 is not associated
with mutation of the other allele. Although haploinsufficiency and/
or further genetic and epigenetic changes remain to be tested this
indicates that NOTCH2 does not present genetic characteristic of a
tumor suppressor gene.
NOTCH2 and 1p/19q Co-Deletion
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identified pericentromeric breakpoints in most cases. In silico study
of 19q contrary to 19p pericentromeric region revealed the
presence of highly repetitive architecture with multiple various
classes of low copy repeat sequences such as Alpha, human satellite
IV (HSAT4) and human endogenous retrovirus (HERVK) repeats
at breakpoint sites (not shown). BLAT analysis of human sequence
assembly showed intra- and interchromosomal sequence similarity
of this locus. In particular it highlighted a high sequence homology
between the two chromosome 19 cluster regions over a more than
50 kb stretch. We may therefore speculate that chromosome 19
pericentromeric loci comprise specific recombination-prone geno-
mic structures leading to chromosomal instability by recombina-
tion-driven rearrangements. Importantly, strong DNA sequence
homology of chromosome 19 to chromosome 1 centromeric and
pericentromeric regions with several common alpha-satellite
sequences was described [21,25]. This suggests that the specific
architecture of these segments might be more prone to
chromosomal rearrangements, thus mediating chromosome
breakage and generating the aforementioned 1p/19q transloca-
tion. Alphoid repeats have already been documented in some
derivatives of the recurrent translocations suggesting genomic
instability as a cause of arm-to-arm translocations in several types
of tumors [26–28]. We cannot exclude other mechanisms that
may be responsible for the profiles revealed by the array-CGH
analysis of these 1p/19q co-deleted cases. Indeed, copy number
polymorphisms encompassing the chromosome 19 breakpoint
regions suggesting that some alternative structure of these regions
may favor 1p/19q recurrent rearrangement in OD cases. It has
been shown, for example, that complex repeat structures with
functionally relevant polymorphism not only presents functional
relevance to promoter activity but also demonstrate genetic
instability in colorectal tumors of the mutator phenotype [29].
However, the peripheral blood versus reference DNA CGH
experiments that were conducted as control experiments in our
work did not identify obvious copy number variations. Finally,
cancer-specific 1p/19q translocation might be facilitated by
general genomic instability associated with alterations of the
pericentromeric chromatin structure by epigenetic perturbation.
Evidence suggests that the hypomethylation process induces
pericentromeric heterochromatin decondensation and contributes
to the instability of the satellite DNA sequences. This may permit
recombination and formation of unstable translocations. Such
decondensation has been described in glioblastoma as well as in
other type of tumors such as facial anomalies syndrome, multiple
myeloma, hepatocellular carcinomas, breast and Wilms tumors
[30–36].
The data presented here revealed that chromosome 1 and 19
status in the tumors displaying t(1;19) recurrent translocations is
more complex than previously thought. In summary, we exclude
NOTCH2 gene as a target of apparent translocation breakpoint
and suggest involvement of the centromere and centromere/
pericentromere sequences of chromosome 1 and 19, respectively,
in the process of translocation. We also reveal novel pericen-
tromeric breakpoint sites on 19p and 19q arms.
Materials and Methods
Clinical material
The current study consisted of oligodendroglioma tumor
samples treated at the Pitie ´-Salpe ˆtrie `re hospital, Paris, France
and previously shown to harbor 1p/19q co-deletion [13]. Tumor
samples were snap-frozen and stored at 280uC immediately after
surgical resection. High molecular weight DNA was isolated from
both tumor and peripheral blood using a standard phenol-
chloroform procedure. All patients gave written informed consent,
as requested by French law, allowing molecular, genetic and
translational research studies on cancer tissue samples. The
analysis was performed on anonymized data.
1 Mb genomic BAC ARRAY-CGH platform
A full-coverage genomic BAC aCGH with an average
resolution of 1 Mb, previously described [11], was used for
DNA copy number analysis. In particular, it contains a set of 402
measurement points localized on 1p, as well as 41 chromosome
loci confined to chromosome 19. In order to increase the
resolution of analysis an additional twenty-five BAC clones in
the vicinity of the chromosome 1 centromere were further selected
for inclusion on the initial 1 Mb array. The procedures for DNAs
extraction, hybridization and washing have been described
previously [13]. Arrays were scanned using a 4000B scan (Axon,
Union city, USA). Image analysis was performed with Genepix 5.1
software (Axon, Union city, USA) and ratios of Cy5/Cy3 signals
were determined.
High density oligonucleotide array-CGH platform
The Agilent eArray platform was used to design oligonucleotide
array-CGH (8615 K, Agilent Technologies, Palo Alto, CA)
providing high resolution over the pericentromeric regions on
chromosome 1p 119,360,001–121,186,599, 1q 141,476,958–
Figure 2. Deletion extends centromeric to NOTCH2 as revealed by the high density oligonucleotide array. The X-axis displays the
oligonucleotide probe order according to their physical position on chromosome 1 in megabases. A position landmark is indicated every 100 probes.
The Y-axis denotes the average normalized fluorescence ratios on a log2 scale. Black diamonds represent the normalized log2 ratio from hybridization
of patient versus reference (normal male) peripheral blood-derived DNAs, used as control experiment. The blue and pink diamonds illustrate
normalized log2 ratios of the patient tumor DNA to the reference or to the matched peripheral blood-derived DNAs, respectively. The red diamonds
above the graphs indicate the probes for which BLAT search displayed only a single chromosomal position within human genome with 100%
sequence identity. (A) log2 ratio plot of a representative oligodendroglioma DNA (OD1786) displaying 500 oligonucleotide probes (119,457,515–
119,619,961) telomeric to NOTCH2 gene. (B) Array-CGH profile of OD1786 displaying probes encompassing the NOTCH2 gene. The positions of the 34
exons (black horizontal bar) of NOTCH2 and the segmental duplication (Dupl; orange horizontal bar) are highlighted above the array-CGH profile.
Probes located within segmental duplication loci displayed quasi-normal fluorescence ratio, consistent with the duplication of this region to 1q21.1.
(C) A pool of 851 single hit probes, including 128 data points covering NOTCH2 gene is visualized. The majority of the probes displayed an average
fluorescence ratio close to 21 (haploid level), consistent with the presence of a deletion. The position of NOTCH2 gene is indicated by a black
horizontal bar. The black box (D) highlights deletion of loci centromeric to NOTCH2. (D) Enlarged, detailed view of the normalized fluorescence log2
ratio for 16 unique loci enclosed by the chromosomal position 120,874,063-121,032,434, centromeric to NOTCH2. The X-axis displays every unique
probe according to its physical position on chromosome 1. The vertical arrows indicate the position of the selected LOH (loss of heterozygosity)-
associated SNP (single nucleotide polymorphism) loci analyzed. (E) LOH at loci distal to NOTCH2. Sequencing data comparing SNPs constitutional (B)
and tumor DNA (T) from the same patient. In (a) and (b) examples of SNPs (rs1923929 and rs2453042, respectively) located within segment of
NOTCH2 gene. (F) Detection of LOH within five SNP loci (c–g) (rs2319971, rs10903156, rs12743661 rs28785495 and rs28793055, respectively) located
centromeric to NOTCH2 gene.
doi:10.1371/journal.pone.0004107.g002
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PLoS ONE | www.plosone.org 5 January 2009 | Volume 4 | Issue 1 | e4107Figure 3. Array-CGH profiles of the representative cases containing deletions affecting chromosome 19. (A) Detection of deletion of
the long arm of chromosome 19 using 1 Mb BAC array-CGH. The general outline of this figure follows Figure 1. The blue diamonds highlight the
supplementary clones in the improved version of a 1 Mb BAC array used in this analysis. (B and C) Array-CGH profiles of two representative tumors
disclosing the presence of continuous 19q deletion extending to: 19p (3B, OD1778) and 19q pericentromeric regions (3C, OD758). The positions of
translocation breakpoints are highlighted by black boxes (E and F). The general outline of the figures follows Figure 2. (D) An example of
oligodendroglioma case (OD1216) disclosing a gain which precedes 19q allelic loss. The positions of the breaks are highlighted by the black boxes (E
NOTCH2 and 1p/19q Co-Deletion
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33,387,097 of the Build 36.1 assembled human genome. In total,
the pericentromeric-specific array consist of 4262 (1p), 4556 (1q),
1011 (19p) and 2406 (19q) measurement points of varying repeat/
duplication content. In particular, total number of data points
comprises 1901 single 100% sequence identity hit probes (128
covering NOTCH2 gene) and these are abbreviated throughout the
paper as unique probes. Finally, 1845 positive and negative
biological control probes (localized on 1q and 19p and other
human autosomes) were included into the array set-up. The
designed array provides an average probe spacing of 377 bp.
Sample amplification, labeling, and hybridization were performed
according to the protocol provided by Agilent Technologies
(8615 K CGH oligonucleotide array-CGH array analyses).
Briefly, 500 ng of genomic DNA was digested with AluI and
RsaI enzymes followed by column purification (Microcon YM-30,
Millipore, Valencia, CA, USA). Digested tumor and reference
DNAs were labeled with Cy5-dUTP and Cy3-dUTP, respectively
(Genomic DNA labeling Kit Plus, Agilent Technologies, Palo Alto,
CA), pooled and hybridized as instructed in the manufacturers
protocol. Agilent scanner was used to obtain ratios of Cy5/Cy3
signals from the targets localized on the array. Normalization (dye
bias and background correction) and analysis of microarray data
was performed using Agilent Feature Extraction (version 9.5.3
Agilent Technologies) and CGH Analytics software’s (version
3.4.40, Agilent Technologies), respectively.
Loss of heterozygosity analysis
To evaluate allelic loss, a panel of 39 and 42 SNPs (single-
nucleotide polymorphisms) on 1p and 1q arm, respectively were
studied. The locations and sequences from the LOH-associated
SNP loci were retrieved from the database at the National Centre
for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.
gov/SNP/). Primers flanking these loci were designed using
Primer3. Oligonucleotide primer pairs for all SNPs were custom
synthesized at MWG Biotech (http://www.the-mwg.com). Direct
sequencing (Big Dye Terminator V3.1) of PCR-amplified locus
fragments from blood and tumor DNA samples was carried out by
3130xl Genetic Analyser (Applied Biosystems, Inc.). Results
obtained from the SNP loci in blood DNA were used as the
baseline to estimate the copy number of the corresponding SNP
loci in the tumor DNA. LOH was scored as present when the
tumor sample showed reduction in height of one of two peaks (two
alleles) by .50%. The consistency of all important results was
validated by repeated analysis on both strands.
Mutation analysis of the NOTCH2 gene
All 34 NOTCH2 encoding exons (Ensemble: EN-
SCAFG00000010476) of four selected oligodendroglioma tumor
and paired peripheral blood derived DNAs were analyzed for
somatic mutations by PCR amplification followed by direct
genomic sequencing of both DNA strands (for additional
information, see supplementary data, Table S2).
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0004107.s001 (0.04 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0004107.s002 (0.07 MB
DOC)
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